Phytonanogel Shield is a topical nanomedicine hydrogel formulated using lipid-based nanoparticles encapsulating eugenol, a plant-derived anti-inflammatory compound. It is designed to manage mild-to-moderate psoriasis by delivering targeted, controlled, and long-acting therapeutic effects without the use of steroids.
The innovation lies in its nanoencapsulation system, which enhances the skin penetration and bioavailability of eugenol. By embedding these nanoparticles in a biocompatible hydrogel matrix, the formulation achieves sustained and controlled drug release over extended durations, maintaining therapeutic efficacy and minimizing the need for frequent application.
Eugenol, derived from clove oil, has well-documented anti-inflammatory, antioxidant, and antiproliferative properties. In psoriasis, it helps suppress keratinocyte hyperproliferation, reduce cytokine-mediated inflammation, and restore skin homeostasis.
Nanoparticles facilitate deeper and more uniform penetration of the active compound into the dermal layers. They allow for localized drug delivery, reducing systemic exposure and side effects. The sustained release profile also ensures prolonged therapeutic action, improving patient compliance and outcomes.
Yes. The formulation contains FDA-approved, plant-derived excipients, and preclinical studies have demonstrated excellent biocompatibility with no observed cytotoxicity, irritation, or systemic toxicity, even with repeated application.
Due to its sustained-release profile, Phytonanogel Shield maintains its therapeutic effect over extended periods. As a result, less frequent application is sufficient compared to traditional steroid-based creams, which require multiple daily applications.
While currently under development for psoriasis, the platform holds potential for adaptation to other inflammatory or hyperproliferative skin disorders, subject to further formulation and clinical validation.
Yes. The formulation is designed using cost-effective, natural ingredients and manufactured via a scalable, solvent-free process. Production costs are approximately ₹10,000–20,000 per kg, allowing pricing below ₹10 per dose, making it highly suitable for large-scale public health deployment.
Absolutely. The product’s affordability, ease of self-application, and stability without refrigeration make it ideal for deployment in resource-limited settings, ensuring equitable access to quality dermatological care.
In vitro keratinocyte models (HaCaT): Reduced inflammatory cytokines and cell proliferation
Ex vivo psoriatic skin: Enhanced drug penetration and barrier restoration
In vivo (imiquimod-induced psoriatic mice): Significant reduction in erythema, scaling, epidermal thickness, and immune cell infiltration, no toxicity or irritation has been observed across models.
Phytonanogel Shield has completed preclinical proof-of-concept studies. The team is now working with regulatory consultants and CRO partners to initiate GLP toxicity studies and prepare for Phase I clinical trials.
Yes. The formulation is free from steroids and harmful chemicals, and all ingredients are FDA-approved. Preclinical studies have shown no toxicity or irritation, even with repeated use.
Absolutely. Traditional treatments range from ₹500 to ₹2000 per dose. Phytonanogel Shield is designed to cost under ₹10 per application, making it highly affordable and accessible to a wider population
We are currently in the preclinical phase and working towards clinical trials. Once approved, the product will be available through dermatologists, pharmacies, and online platforms.
NanoTherapX was founded by Dr. Roshan Keshari, a biomedical innovator, with mentorship from leading professors at IIT Bombay. The company is built on the vision of translating lab research into affordable, inclusive healthcare.
NanoTherapX aims to become a leading provider of affordable, plant-based nanomedicines for chronic skin conditions and other inflammatory disorders. Our mission is to translate cutting-edge science into inclusive healthcare solutions that are safe, scalable, and accessible to underserved populations globally.
Yes. The underlying phyto-nanoparticle hydrogel platform is modular and adaptable. We are currently exploring extensions into other chronic conditions such as eczema, atopic dermatitis, acne, and even cosmeceutical applications like anti-aging and scar treatment.
We are actively engaging with CROs for regulatory and clinical development, academic collaborators for validation, and seeking partnerships with pharmaceutical manufacturers and distribution networks to enable large-scale deployment post-approval.
Affordability is built into our product design. We use low-cost, FDA-approved ingredients and a solvent-free, scalable manufacturing process. Additionally, we aim to partner with government health programs, NGOs, and public hospitals to ensure availability in rural and low-income communities.
Our innovation aligns with SDG 3 (Good Health and Well-being) and SDG 9 (Industry, Innovation & Infrastructure) by promoting sustainable, inclusive innovation in healthcare that can reduce the burden of chronic disease and improve quality of life at scale.
Yes. We are actively exploring strategic collaborations, co-development opportunities, and licensing models with pharma companies, research institutions, and public health agencies to accelerate translation and broaden our impact.
Development & Vision FAQs
Get in Touch Instantly 💬
“Have a question? Drop your details, and we’ll reach out soon”
Connect With Us Instantly
Got a question? Share your details and our team will get back to you shortly.
